Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials

Biliary tract cancer (BTC) compromises a heterogenous group of tumors with poor prognoses. Curative surgery remains the first choice for localized disease; however, most BTC patients have had unresectable or metastatic disease. The gold standard therapy for these patients is chemotherapy with gemcit...

Full description

Bibliographic Details

Published in:	Biomolecules
Main Authors:	Nai-Jung Chiang, Li-Tzong Chen, Yan-Shen Shan, Chun-Nan Yeh, Ming-Huang Chen
Format:	Article
Language:	English
Published:	MDPI AG 2021-01-01
Subjects:	biliary tract cancer next-line therapies clinical trials
Online Access:	https://www.mdpi.com/2218-273X/11/1/97